What you search does not exist. Please visit our home page, maybe you'll find what you're looking for.

License signed with Novartis on the work of Professor Guillaume Canaud’s team

On May 13, 2022, Inserm Transfert announced the signature of a license agreement with Novartis for the work resulting from the research of Prof. Guillaume Canaud’s team at the Institut Necker – Enfants Malade (INEM), of which Inserm is one of the supervisors.

This research aims to reposition Alpelisib for CLOVES (Congenital Lipomatous Overgrowth, Vascular Malformation, Epidermal Nevi) syndrome. It is intended in particular to relieve and treat young children suffering from severe forms of this disease. This announcement follows the marketing authorization of Alpelisib granted by the FDA in mid-April following clinical trials conducted at the Necker Hospital.

Inserm Transfert press release 👉🏽 https://www.inserm-transfert.fr/storage/2022/05/CP-Syndrome-Cloves-Pr-Canaud_Inserm-Transfert_vf.pdf (in French)

Video #5 – The role of Pierani’s group at Imagine Institute in the RHU-COSY

The COSY consortium (Cure Overgrowth Syndromes), a 5-year scientific project funded by the French National Research Agency (ANR) within the framework of the “Investissement d’Avenir” (PIA) programs, focuses on the treatment of overgrowth syndromes. We regularly offer videos that allow you to better understand the role of each of the RHU-COSY partner. Indeed, the project combines all the necessary skills to propose innovative tools in physiopathology, genetics, imaging and reorganization of care for overgrowth syndromes. The complementarity of the different actors of the project is essential to its success.

We invite you to discover today the involvement of the Alessandra Pierani’s group “Genetics and development of the cerebral cortex” at Imagine Institute, Paris in the RHU-COSY.

Video #4 – The role of CREATIS and the HCL in the RHU-COSY

The COSY consortium (Cure Overgrowth Syndromes), a 5-year scientific project funded by the French National Research Agency (ANR) within the framework of the “Investissement d’Avenir” (PIA) programs, focuses on the treatment of overgrowth syndromes. We regularly offer videos that allow you to better understand the role of each of the RHU-COSY partner. Indeed, the project combines all the necessary skills to propose innovative tools in physiopathology, genetics, imaging and reorganization of care for overgrowth syndromes. The complementarity of the different actors of the project is essential to its success.

We invite you to discover today the involvement of the CREATIS laboratory and the “Hospices Civils de Lyon”, the two Lyon-based partners of the consortium, in the RHU-COSY.

Video #3 – The role of the Foundation For Rare Diseases in the RHU-COSY

COSY is a joint initiative of 11 partners, comprising two hospitals (Necker – Enfants Malades – AP HP and Hôpital Mère Enfant – HCL), 6 research groups (including hospital-university instituts (Instituts Hospitalo- Universitaires (IHUs), 3 industrial partners and one patient association. It combines all the necessary skills to propose innovative tools in physiopathology, genetics, imaging and care reorganization.

We invite you to discover the role of the Foundation for Rare Diseases in this french video with Diana DĂ©sir-Parseille, Anne-Sophie Blancher and the Prof Daniel Scherman

Happy New Year 2022

 

All the members of the consortium 
wish you a Happy New Year 2022! 


May this year be prosperous for patients 
with overgrowth syndromes, with many successes 
and achievements for the COSY project.

Support from the Association Syndrome Cloves

A big thank to the Association Syndrome Cloves for his generous support for the research work carried out by Prof. Canaud’s teams on dysharmonious hypergrowth syndrome and vascular anomalies.
 
Thanks to the Fondation Sodebo, Saint Herblain Triathlon, Clarisse Naud Ex Verre Bouteille, Culture en Fête à Romillé (35), Union sportive et culturelle à Chavagne (35), Collège Sainte-Thérèse du Mesnil Saint-Denis.

Book “Qui a tuĂ© Cloves ?”

Book “Qui a tuĂ© Cloves ?”

Ce livre est l’histoire d’une première mĂ©dicale mondiale : aucun traitement n’Ă©tait disponible avant. Le frère de Guillaume, Axel SĂ©nĂ©quier, a rencontrĂ© les protagonistes de cette aventure hors norme : il raconte les doutes et les espoirs de l’Ă©quipe de l’hĂ´pital Necker, dresse des portraits bouleversants des jeunes patients et de leur famille et fait dĂ©couvrir au grand public les coulisses d’une dĂ©couverte mĂ©dicale qui peut sauver la vie Ă  des milliers d’enfants Ă  travers le monde.

02/09/2021
Editeur Hygee
Collection Plumes
Format11cm x 17cm
Nombre de pages218

https://livre.fnac.com/a15937788/Axel-Senequier-Qui-a-tue-Cloves

Video #2 – What is the role of each member of the Prof Canaud ‘s team ?

COSY is a joint initiative of 11 partners, comprising two hospitals (Necker – Enfants Malades – AP HP and Hôpital Mère Enfant – HCL), 6 research groups (including hospital-university instituts (Instituts Hospitalo- Universitaires (IHUs), 3 industrial partners and one patient association. It combines all the necessary skills to propose innovative tools in physiopathology, genetics, imaging and care reorganization.

We invite you to open the doors of the laboratory to discover the role of the members of Professor Guillaume Canaud’s team.

In this second video, you’ll discover :

Dr Junna Yamaguchi, MD, PhD (Postdoc)
Rubina Cassaca, Scientific Project Manager

To know more : https://rhu-cosy.com

The Congres Tor de France


The RHU-Cosy was partner of the TOR of France. It took place on October 14 and 15 in Nice, as planned, after 3 successive postponements due to the Covid-19 crisis.  There were 139 (81 on site + 58 online).

The exchanges were of high quality and the discussions made it possible to establish links that would not have seen the light of day otherwise.

 For more informations : https://www.tor-de-france.fr